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On 6 May 2020, the UK Prime Minister, Boris Johnson, quoted statistician David 
Spiegelhalter, arguing that it was not appropriate to compare the COVID-19 death rate in the 
UK with other countries(1). Within a few hours, Spiegelhalter tweeted a request for the Prime 
Minister to stop quoting him and affirmed that “of course we should now use other countries 
to try and learn why our numbers are high” (2).  
The issue was that, although it is difficult to reliably compare COVID-19 population fatality 
rates between countries, it is also quite clear that some countries (e.g. UK, USA, Italy, Spain, 
Belgium, France) have markedly higher burdens of COVID-19 mortality than others (e.g. 
New Zealand, Australia, Singapore, South Korea, Germany). While one could not say 
definitively that the UK was the worst in the world, it was performing worse than some 
countries which had tried alternative control strategies, and there are things that we can learn 
from that contrast. 
Indeed, epidemiology is built on the idea of studying differences between populations.  Much 
of what we have learnt about the causes of disease has had its origins in comparisons of 
countries(3, 4). For example, in the 1950s, it was realised that colorectal cancer risks were 
high in Europe and low in Africa, possibly due to dietary differences in fibre from fruit and 
vegetable intake.  Similarly, liver cancer was common in Asia, which eventually provided a 
link to hepatitis B. International differences in cervical cancer incidence and mortality 
suggested an infectious cause, later established as human papillomavirus (HPV). 
COVID-19 is different. The causative agent, SARS-CoV-2, is clear; the task is to learn how 
to best block the virus’s transmission and to prevent infections from progressing to severe 
disease and death.  
As the pandemic unfolds, there are numerous natural experiments in progress, as countries 
adopt different approaches. Although international comparisons are often disparaged because 
of different data quality and fears of the ‘ecological fallacy’, if done carefully they can play a 
major role in our learning what works best for controlling COVID-19 (3). Furthermore, these 
natural experiments are yielding clear results within weeks or months (e.g. on the success of 
the Asian approaches). Thus, there needs to be more thoughtful and thorough analyses of 
country differences, done by experienced epidemiologists, as it is probably the most 
important and most valid evidence for informing COVID-19 policy in real time  
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And after all, what is the alternative? It is impossible or unethical to randomize a lockdown, 
or other aspects of physical distancing. There could be trials of intensive population 
testing(5), or prophylactic treatment of household contacts, but few have been launched to 
date. And all the time, the COVID-19-clock ticks relentlessly on, accumulating more deaths 
and more survivors with debilitating long-term health problems. 
Perhaps the biggest global difference has been the approach taken to the timing and intensity 
of testing and social distancing. Learning from their experiences of the coronavirus that 
causes SARS(6), governments in Asia (e.g. China, Hong Kong, Taiwan, Singapore, South 
Korea), soon followed by Australia and New Zealand (which is the only country to publish an 
elimination strategy(7)), took action early and decisively. There are differences across Asian 
countries, with most favouring rapid lockdowns, while South Korea, for example, quickly 
mobilized intensive mass testing and contact tracing without the need for a full-scale 
lockdown; Taiwan also avoided the need for a lockdown and has achieved some of the lowest 
population infection rates recorded(8). In contrast, many European and North American 
countries were ready (more or less) to tackle pandemic influenza, but were not prepared for a 
coronavirus pandemic, even though the possibility of such a pandemic had been often 
discussed. Many countries took action too late and/or indecisively (with important exceptions 
such as Greece and Germany). They lost critical time, and the delays to action have cost 
lives. As the virus now spreads across nations in South America and Africa, the lessons from 
these differences in response take on even greater importance. 
However, appropriate inter-country comparisons are not going to be easy. Sweden has been 
an outlier in its relaxed approach to lockdowns. But who should Sweden be compared to? 
The population fatality rate in the UK (472 per million on 11/5/2020) is, at this time, higher 
than Sweden (322); but maybe Sweden, as a Scandinavian country with some ‘innate 
physical distancing’ and a different socio-economic structure is more comparable to Denmark 
(92), Norway (40), Finland (49) or even Australian and New Zealand (4). The comparisons 
are not helped by major differences in case definitions and quality – for example, the death 
rate in Belgium is among the highest in the world, but likely because it includes suspected 
COVID-19 deaths in the totals, whereas many other countries do not. Other data problems 
include COVID-19 deaths being missed due to lack of testing or poor test sensitivity, and 
deaths misclassified as being from COVID-19 rather than just with COVID-19(9). This has 
led some to argue that the only reliable data on the pandemic’s impact on mortality will be 
measures of excess total mortality, which account for COVID-19 deaths that have not been 
4 
 
identified, as well as deaths from other causes related to the lockdown and/or changes in 
health service provision (10). Even then, there are issues as to the time periods to consider. 
The advocates of Sweden’s startling approach have argued that the country’s apparently high 
death rate simply reflects deaths brought forward (i.e. individuals who were going to die later 
in the year anyway) and that other countries are just trying to delay the inevitable.  This 
seems to be an extremely risky approach(11), and preliminary UK data suggests that COVID-
19 deaths are not all ‘deaths brought forward’, and that each death on the average, represents 
about 13 years of healthy life lost (12).  
As time goes on and lockdowns are lifted, more international differences will become 
apparent. For example, there are policy differences in whether face masks are recommended 
or required in public places. And there are major questions about how schools should be 
opened, who should return to work, and what aspects of physical distancing should be 
maintained. Some of these questions can be answered within countries with epidemiological 
studies such as the test-negative design(13), but some require country-to-country 
comparisons.  Of course, we will know more in a year, but we have to take decisions now (as 
the Danish philosopher Kierkegard noted in 1843: "Life can only be understood backwards;  
but it must be lived forwards”). Policymakers must look to other countries’ actions and 
outcomes from this first wave of infection and put themselves in a better position to prepare 
for the next. 
So what are the post-Covid-19 implications for epidemiology?  
Firstly, international collaboration has been essential for making rapid progress on COVID-
19(14). There has been a remarkable alliance of health researchers internationally who have 
worked together to tackle the problem (often while politicians have not). We need to 
strengthen these international ties, and build more international collaborations, particularly 
between high-income-countries and low-and-middle-income countries(15, 16), rather than 
staying within our national silos(17).   
Secondly, we must ensure that the scientific advisory committees include diverse voices, 
including a range of epidemiological approaches. In the early stages of the epidemic, the 
evidence from Asia on the effectiveness of lockdowns and mass testing was largely 
overlooked by countries such as the UK (which initially did not even consider these options), 
where the advisory committees were (and are) dominated by infectious disease modellers, 
behavioural scientists and laboratory scientists. There is a notable lack of other infectious 
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disease epidemiologists who are experienced at collecting and analysing real data (e.g. 
population surveys of infection prevalence which provide essential information for policy(9), 
and analyses of interventions such as those that had already been done in Asia); there is also a 
notable lack of public health specialists with on-the-ground experience in epidemic control 
(including mass testing).  
Thirdly, there is an unmet need for effective global surveillance systems for both infectious 
and chronic diseases (18, 19). Many of these cannot be validly identified from routine health 
system data in low-and-middle-income countries, so worthwhile initiatives like the Global 
Burden of Diseases (GBD) will not pick them up. Regular population disease monitoring is 
also important so that surveillance systems are in place when epidemics occur. Of course, it is 
not possible to conduct comprehensive surveys of all health conditions all of the time. 
However, many low-and-middle-income countries are already conducting surveys such as 
WHO’s STEPS(20), as well as surveys of particular diseases(21). These provide an 
infrastructure which can be the basis for more integrated surveillance systems, which can be 
used to quickly conduct population surveys in an epidemic, thus allowing the estimation of 
important important quantities such as the infection fatality rate and attack rate, and ongoing 
monitoring of the epidemic (9). 
Finally, the COVID-19 epidemic shows the need for epidemiology to go back to its roots – 
thinking about populations(3). Studying disease occurrence by person, place and time (often 
referred to as “descriptive epidemiology”) is usually taught in introductory courses, even if 
this approach is then paid little attention subsequently. COVID-19 is a striking example of 
how we can learn a great deal from comparing countries, states, regions, time trends, and 
persons, despite of all of the difficulties. Epidemiology is a process of discovery(22) and 
testing of multiple hypotheses, putting diverse sets of information together. Population 
comparisons provide the basis for this process, and a ‘reality check’ for almost everything 
else we do subsequently. The first questions we should always be asking are “who gets the 
disease, and who doesn’t, and what can we learn from this?”  
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